Wall Street analysts predict that Esperion Therapeutics Inc (NASDAQ:ESPR) will post sales of $94.92 million for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Esperion Therapeutics’ earnings. The highest sales estimate is $150.00 million and the lowest is $75.00 million. The business is scheduled to report its next quarterly earnings results on Wednesday, May 1st.
According to Zacks, analysts expect that Esperion Therapeutics will report full year sales of $116.26 million for the current financial year, with estimates ranging from $93.75 million to $150.00 million. For the next fiscal year, analysts forecast that the company will post sales of $152.05 million, with estimates ranging from $7.10 million to $229.16 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Esperion Therapeutics.
ESPR has been the topic of several recent research reports. Stifel Nicolaus increased their price objective on Esperion Therapeutics from $89.00 to $104.00 and gave the company a “buy” rating in a research report on Monday, December 10th. Goldman Sachs Group initiated coverage on Esperion Therapeutics in a research report on Thursday, December 13th. They set a “sell” rating and a $45.00 price objective on the stock. BidaskClub lowered Esperion Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, December 25th. ValuEngine lowered Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, January 2nd. Finally, Needham & Company LLC increased their price objective on Esperion Therapeutics from $94.00 to $114.00 and gave the company a “strong-buy” rating in a research report on Monday, January 7th. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $73.69.
In related news, CEO Timothy M. Mayleben bought 5,000 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The stock was bought at an average cost of $48.73 per share, for a total transaction of $243,650.00. Following the acquisition, the chief executive officer now directly owns 51,163 shares of the company’s stock, valued at approximately $2,493,172.99. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Target N. V. Biotech bought 80,000 shares of the company’s stock in a transaction that occurred on Friday, January 4th. The shares were bought at an average price of $41.29 per share, with a total value of $3,303,200.00. Following the completion of the acquisition, the insider now directly owns 3,472,964 shares in the company, valued at $143,398,683.56. The disclosure for this purchase can be found here. Insiders have purchased a total of 145,000 shares of company stock valued at $6,458,750 over the last 90 days. 14.50% of the stock is currently owned by company insiders.
A number of hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC increased its holdings in shares of Esperion Therapeutics by 8.0% in the 4th quarter. Geode Capital Management LLC now owns 275,410 shares of the biopharmaceutical company’s stock worth $12,668,000 after purchasing an additional 20,403 shares in the last quarter. Norges Bank purchased a new position in shares of Esperion Therapeutics in the 4th quarter worth $5,536,000. FMR LLC boosted its stake in shares of Esperion Therapeutics by 43.8% in the 4th quarter. FMR LLC now owns 739,289 shares of the biopharmaceutical company’s stock worth $34,007,000 after buying an additional 225,205 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Esperion Therapeutics by 158.4% in the 4th quarter. Millennium Management LLC now owns 82,536 shares of the biopharmaceutical company’s stock worth $3,797,000 after buying an additional 50,599 shares during the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of Esperion Therapeutics by 33.3% in the 4th quarter. Legal & General Group Plc now owns 9,416 shares of the biopharmaceutical company’s stock worth $434,000 after buying an additional 2,350 shares during the last quarter. Institutional investors own 99.84% of the company’s stock.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Further Reading: How can investors find ex-dividend dates?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.